Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuji Sato

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Transplantation|March 9, 2005
Enrichment of hepatocytes differentiated from mouse embryonic stem cells as a transplantable sourceYuji Kumashiro, Kinji Asahina, Rie Ozeki, et al.
International Journal of Hematology|May 28, 2017
Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populationsKeiji Nogami, Midori Shima, Katsuyuki Fukutake, et al.
International Journal of Hematology|November 18, 2017
Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populationsKeiji Nogami, Midori Shima, Katsuyuki Fukutake, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Transplantation|March 9, 2005
Enrichment of hepatocytes differentiated from mouse embryonic stem cells as a transplantable sourceYuji Kumashiro, Kinji Asahina, Rie Ozeki, et al.
International Journal of Hematology|May 28, 2017
Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populationsKeiji Nogami, Midori Shima, Katsuyuki Fukutake, et al.
International Journal of Hematology|November 18, 2017
Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populationsKeiji Nogami, Midori Shima, Katsuyuki Fukutake, et al.
Pageof 5